Abstracts

Abstracts Submission Opens:

30 June 2025

The ISOLS abstract deadline is 15th February 2026.

All abstracts will be peer-reviewed, and the authors will be notified of the outcome by 10th April 2026.

Presenting Author’s registration deadline is 31st July 2026.

Before accessing the submission form, please make sure that you have prepared your abstract according to the following guidelines:

    • Abstracts can be submitted for Oral or Poster Presentation.
    • Abstracts can only be submitted electronically through the online abstract submission form available at the top of this webpage and should be submitted by February 15, 2026, at the very latest.
    • Acknowledgment of receipt of your submission will be sent to your stated e-mail address. If you do not receive the confirmation e-mail within 24 hours, please contact us at info@isols2026.org.
    • Abstracts must be written in English.
    • In the title, please use capital letters only where necessary.
    • Authors’ names must be listed with mixed-case letters (first name and family name in full). Affiliations (institute/hospital/university, city, country) should be properly stated in your abstract in lowercase. A maximum of 3 institutions per author is allowed.No references to the exact addresses (street number, ZIP) are needed and will be deleted for reasons of uniformity.
    • Abstract texts should have the following structure:
      a) Introduction
      b) Method
      c) Results
      d) Conclusion
    • The text must be a maximum of 450 words, excluding the title, authors list and affiliations.
    • It is the author’s responsibility to submit a complete abstract in a finalized format. Any errors in spelling, grammar, or scientific facts will be reproduced as typed by the author. Changes and editing can be made until the deadline of February 15, 2026. In case of a mistake during the submission, it is not necessary to submit a “new abstract”, please contact the Meeting Organizing Secretariat at info@isols2026.org.
    • The presenting author is indicated by clicking on the appropriate box next to the respective name. The same author can present a maximum of three (3) abstracts. Co-authorship is open to an unlimited number of abstracts.
    • Pre-registration of the abstract’s presenting author by July 31, 2026, is a prerequisite for its presentation in the Scientific Program and its publication in the Meeting electronic material.
    • If the study has been supported by a grant, please indicate the source of funding at the bottom of your abstract. The number of references (if any) should be placed in the order they appear in the abstract.
    • If an author wishes to withdraw a submitted abstract, a written request should be sent to the Meeting’s Secretariat.
    • Submission of closely related abstracts from the same group is discouraged.
    • Abstracts will only be considered for presentation if they are not published or submitted for presentation elsewhere.
    • The punctual submission of abstracts is also a prerequisite for their acceptance. Any submitted abstract that does not meet the above requirements will not be accepted.
  • Notification of acceptance or rejection of the abstract will be sent to the corresponding author of each abstract by April 10, 2026.
  • Accepted abstracts will be considered for oral or poster presentations.
  • The corresponding author receives all information concerning the abstract and is responsible for informing all other co-authors of the status of the abstract.
  • All abstract presenters will be asked to reconfirm their attendance after receiving the notification. If you do not reconfirm your abstract presentation, register, and pay the registration fee before the given deadline, your abstract will be removed from the program.
  1. Authors can modify the author information, category and core data of their abstract directly on the submission system until the deadline given. Please be aware that no extension will be granted.
  2. By submitting an abstract, submitters understand that their abstract, including names, is stored electronically and will be published by the Organizing Committee on the ISOLS 2026 website. Failure to present the abstract on-site will result in exclusion from online publishing.
  3. Abstracts will be assessed by an expert panel of reviewers. Acceptance of the submitted work is at the discretion of the Scientific Committee.
  4. Consent for publication of individual patient data (applies to abstracts with identifiable patient information): For publication of an abstract that contains identifiable information about patients, it is necessary that patients have given consent for the research to be published. For all abstracts that include identifiable patient details (e.g. gender, age, illness, location) or images, written informed consent must be obtained from the patient (or their parent or legal guardian) and a respective statement should be included in the abstract text.
  5. Duplication of publication: ISOLS does not accept re-submission; abstracts must correspond to original, previously unpublished work. By submitting an abstract, the submitter confirms that he/she has not presented/plans to present and publish the abstract at another meeting, and that he/she has not submitted/published the full paper.
  6. Declaration of Conflict of Interest: ISOLS is committed to ensuring the integrity of its scientific, educational, and research programs. Abstract submission requires disclosure of any financial or other interest that might be construed as resulting in an actual, potential, or apparent conflict. The submitter is responsible for obtaining disclosure information from all co-authors, to be entered in the author section of the submission page.

For any queries regarding the online abstract submission, please contact the Meeting Organizing Secretariat at info@isols2026.org.